276 related articles for article (PubMed ID: 23047001)
1. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
3. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
[TBL] [Abstract][Full Text] [Related]
6. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
7. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
[TBL] [Abstract][Full Text] [Related]
9. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
[TBL] [Abstract][Full Text] [Related]
10. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
[TBL] [Abstract][Full Text] [Related]
15. Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.
Gentile G; Bernasconi G; Pozzan A; Merlo G; Marzorati P; Bamborough P; Bax B; Bridges A; Brough C; Carter P; Cutler G; Neu M; Takada M
Bioorg Med Chem Lett; 2011 Aug; 21(16):4823-7. PubMed ID: 21764580
[TBL] [Abstract][Full Text] [Related]
16. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.
Mohammad M; Al-Masri IM; Issa A; Al-Ghussein MA; Fararjeh M; Alkhatib H; Taha MO; Bustanji Y
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):690-4. PubMed ID: 22512725
[TBL] [Abstract][Full Text] [Related]
17. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β.
Cociorva OM; Li B; Nomanbhoy T; Li Q; Nakamura A; Nakamura K; Nomura M; Okada K; Seto S; Yumoto K; Liyanage M; Zhang MC; Aban A; Leen B; Szardenings AK; Rosenblum JS; Kozarich JW; Kohno Y; Shreder KR
Bioorg Med Chem Lett; 2011 Oct; 21(19):5948-51. PubMed ID: 21873061
[TBL] [Abstract][Full Text] [Related]
20. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
